Devonian Reports Positive Results in MASH Liver Study
In a great collaboration with Devonian Health Group Inc., we are happy to demonstrate preclinical proof of concept for Thykamine™ using our STAM (MASH-HCC model) mouse.
Thykamine™ treatment in STAM mice demonstrated improvements in NAS and fibrosis—key endpoints in clinical trials. Beyond atopic dermatitis and ulcerative colitis, Thykamine™ has also shown promising anti-inflammatory and anti-fibrotic effects in liver disease, highlighting its potential for broader therapeutic applications.
We look forward to its continued development and success.
For more details, please see the press release: